Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy

    NEXT STORY
    Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients
    PREV STORY
    Teleflex to Present at the 31st Annual Piper Jaffray Healthcare Conference
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Global Tourniquet Market 2018-2024 with Zimmer Biomet, Stryker, Delfi Medical Innovation, Ulrich GmbH, and Hammarplast Medical Dominating

    author_avatar
    NASDAQ Market News

    European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia

    author_avatar
    NASDAQ Market News

    CRISPR Therapeutics Announces Oral Presentation at the 55th Annual Meeting of the European Association for the Study of Diabetes

    author_avatar
    NASDAQ Market News